| 摘要 |
<p>Discloses a method of predicting the course of disease in a patient having a malignant melanoma, the method comprising determining in melanoma cells comprised in a sample obtained from said malignant melanoma the presence or amount of at least five biomarkers selected from the group comprising or consisting of MTAP, PTEN, Bax, Bcl-X, beta-Catenin, CD20, Cox-2, CD49d and MLH1, wherein the absence or decreased amount of MTAP and beta-Catenin and/or the presence or increased amount of PTEN, Bax, Bcl-X, CD20, Cox-2, CD49d and MLH1 is associated with a disadvantageous course of disease. Also discloses a method of preparing a tailored pharmaceutical composition for a patient having a malignant melanoma using the same biomarkers.</p> |
